

Research Article



A FACTORIAL STUDY ON ENHANCEMENT OF SOLUBILITY AND DISSOLUTION RATE OF IBUPROFEN BY HYDROXY PROPYL β CYCLODEXTRIN AND SOLUTOL HS15

K.P.R. Chowdary, Annamma Devi G.S^{*}, K. Dhanalakshmi

AU College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, A.P, India.

^{*}Corresponding author's E-mail: annammadevi.sayam2011@gmail.com

Accepted on: 03-09-2012; Finalized on: 31-10-2012.

ABSTRACT

Ibuprofen, a widely prescribed anti-inflammatory drug belongs to class II under BCS and exhibit low and variable oral bioavailability due to its poor aqueous solubility. It is practically in soluble in water and aqueous fluids. As such its oral absorption is dissolution rate limited and it requires enhancement in the solubility and dissolution rate for increasing its oral bioavailability. The objective of the present study is to enhance the solubility and dissolution rate of ibuprofen by the use of Hydroxy Propyl β cyclodextrin (HP β CD) and Solutol HS15 (non ionic surfactant). The individual main effects and combined (or interaction) effect of HP β CD (Factor A) and Solutol HS15 (Factor B) in enhancing the solubility and dissolution rate of ibuprofen were evaluated in a 2² factorial study. The individual and combined effects of HP β CD and Solutol HS15 in enhancing the solubility of ibuprofen were highly significant ($P < 0.01$). Solutol HS 15 alone gave highest enhancement (42.64 fold) in the solubility of ibuprofen. HP β CD alone gave 4.06 fold increases and in combination with Solutol HS 15 it gave 21.88 fold increases in the solubility of ibuprofen. The individual main and combined (interaction) effects of HP β CD (Factor A) and Solutol HS15 (Factor B) in enhancing the dissolution rate (K_1) and dissolution efficiency (DE_{30}) were highly significant ($P < 0.01$). HP β CD and Solutol HS15 alone gave respectively 10.80 and 19.10 fold increase in the dissolution rate of (K_1) of ibuprofen and in combination they gave a 38.05 fold increase in the dissolution rate (K_1) of ibuprofen. Combination of HP β CD with Solutol HS15 resulted in a much higher enhancement in the dissolution rate of ibuprofen than is possible with them alone. Hence a combination of HP β CD and Solutol HS15 or Solutol HS15 alone is recommended to enhance the solubility, dissolution rate and dissolution efficiency of ibuprofen, a poorly soluble BCS class II drug.

Keywords: Ibuprofen, Solubility, Dissolution Rate, Hydroxy Propyl β Cyclodextrin, Solutol HS15.

INTRODUCTION

Ibuprofen, a widely prescribed anti-inflammatory drug belongs to class II under BCS and exhibit low and variable oral bioavailability due to its poor aqueous solubility. It is practically in soluble in water and aqueous fluids. As such its oral absorption is dissolution rate limited and it requires enhancement in the solubility and dissolution rate for increasing its oral bioavailability. Several conventional methods such as micronization, chemical modification, use of surfactants and solubilizers, solid dispersion and a few new emerging technologies such as cyclodextrin complexation, mucoadhesive microspheres, nanoparticles, nanosuspensions, micro emulsion and self-emulsifying systems are available to enhance the solubility, dissolution rate and bioavailability of poorly soluble BCS Class II drugs¹. Among the various approaches complexation with cyclodextrins has gained good acceptance in recent years in industry for enhancing the solubility and dissolution rate of poorly soluble drugs. Cyclodextrins (CDs) are cyclic torus-shaped molecules with a hydrophilic outer surface and a lipophilic central cavity which can accommodate a variety of lipophilic drugs. As a consequence of inclusion process many physico-chemical properties such as solubility, dissolution rate, and bioavailability can be favourably affected^{2, 3}. Cyclodextrins have been receiving increasing application in pharmaceutical formulation in recent years due to their approval by various regulatory agencies^{4,5}.

Surfactants increase the solubility of lipophilic water-insoluble drugs by micellar solubilization. Solutol HS15, a non ionic surfactant consists of polyglycol mono- and diesters of 12-hydroxystearic acid with about 30% polyethylene glycol. Solutol HS15 has been shown to be safe in various animal toxicity models. Solutol HS15 has been approved in Canada and Argentina in marketed injectable drug products. Solutol HS15 has been used as an excellent solubilizer for liquid-filled capsules⁶. It is also reported as a carrier for solid dispersions of nifedipine for enhancing its dissolution rate⁷.

Though cyclodextrin complexation and use of Solutol HS15 for enhancing the solubility and dissolution rate of poorly soluble drugs have been investigated individually, no reports are available on their combined use in enhancing the solubility and dissolution rate of poorly soluble drugs. The objective of the present study is to enhance the solubility and dissolution rate of ibuprofen by the use of hydroxy propyl β cyclodextrin (HP β CD) and Solutol HS15. The individual main effects and combined (or interaction) effect of HP β CD and Solutol HS15 in enhancing the solubility and dissolution rate of ibuprofen were evaluated in a 2² factorial study.

MATERIALS AND METHODS

Materials

Ibuprofen was a gift sample from M/s. Eisai Pharmatechnology and Manufacturing Pvt. Ltd., Visakhapatnam. Hydroxy propyl β Cyclodextrin was gift



sample from M/s. Cerestar Inc., USA. Methanol (Qualigens) and Solutol HS15 were procured from commercial sources. All other materials used were of pharmacopoeial grade.

Methods

Estimation of Ibuprofen

An UV Spectrophotometric method based on the measurement of absorbance at 221 nm in phosphate buffer at pH 7.2 was used for the estimation of ibuprofen. The method was validated for linearity, accuracy, precision and interference. The method obeyed Beer's law in the concentration range of 0-10 µg/ml. When a standard drug solution was repeatedly assayed (n=6), the relative error and coefficient of variance were found to be 0.85% and 1.20 % respectively. No interference by the excipients used in the study was observed.

Solubility Determination

Excess drug (50 mg) was added to 15 ml of each fluid taken in a 25 ml stoppered conical flask and the mixtures were shaken for 24 h at room temperature (28±1°C) on Rotary Flask Shaker. After 24 h of shaking, 2 ml aliquots were withdrawn at 2 h interval and filtered immediately using a 0.45 µ disk filter. The filtered samples were diluted suitably and assayed for ibuprofen by measuring absorbance at 221 nm. Shaking was continued until two consecutive estimations are the same. The solubility experiments were replicated for four times each (n=4).

Preparation of Ibuprofen - HPβCD Complexes

Solid inclusion complexes of ibuprofen – HPβCD – Solutol HS 15 were prepared as per 2² – factorial study by kneading method. Ibuprofen, HPβCD and Solutol HS 15 were triturated in a mortar with a small volume of solvent consisting of a blend of water: methanol (1:1). The thick slurry formed was kneaded for 45 min and then dried at 55°C until dry. The dried mass was powdered and sieved to mesh No. 120.

Dissolution Rate Study

The dissolution rate of ibuprofen as such and from HPβCD complexes prepared was studied in 900 ml phosphate buffer at pH 7.2 using Disso 2000 (Labindia) 8-station dissolution test apparatus with a paddle stirrer at 50 rpm. A temperature 37±1°C was maintained throughout the study. Ibuprofen or ibuprofen - HPβCD complex equivalent to 50 mg of ibuprofen was used in each test. Samples of dissolution media (5 ml) were withdrawn through a filter (0.45 µ) at different intervals of time, suitable diluted and assayed for ibuprofen at 221 nm. The sample of dissolution fluid withdrawn at each time was replaced with fresh fluid. The dissolution experiments were replicated three times each (n=3).

Analysis of Data

Solubility and dissolution data were analyzed by Analysis of Variance (ANOVA) as per 2² factorial study.

RESULTS AND DISCUSSION

The individual main and combined (interaction) effects of HPβCD (Factor A) and Solutol HS15 (Factor B) on the aqueous solubility of ibuprofen were evaluated in a 2²-factorial experiment. For this purpose, two levels of HPβCD (0, 5 mM) and two levels of Solutol HS15 (0, 2%) were selected and the corresponding four treatments involved in the 2²-factorial study were purified water (1); water containing 5 mM HPβCD (a); water containing 2% Solutol HS15 (b) and water containing 5 mM HPβCD and 2% Solutol HS15 (ab).

The solubility of ibuprofen in the above mentioned fluids was determined (n=4) and the results are given in Table 1.

The solubility data were subjected to Analysis of Variance (ANOVA) to find out the significance of main and combined effects of HPβCD and Solutol HS15 on the solubility of ibuprofen.

Table 1: Solubility of Ibuprofen in Various Fluids as per 2² - Factorial Study

Fluids (Code as per 2 ² - Factorial Experiment)	Solubility (mg/100 ml) (n=4) (\bar{x}) (s.d)	Increase in Solubility (Number of Folds)
Distilled water (1)	12.42±0.32	---
Water containing 5 mM HPβCD (a)	50.39±1.91	4.06
Water containing 2% Solutol HS 15 (b)	529.59±13.03	42.64
Water containing 5 mM HPβCD and 2% Solutol HS 15 (ab)	271.79±11.40	21.88

Table 2: ANOVA of Solubility Data

Source of Variation	D F	S.S	MSS (SS/DF)	F – Ratio
Total	15	682194.91	45479.65	
Treatment	3	681283.77	227094.58	2990.95
Error	12	911.12	75.92	
Factor A	1	48321.93	48321.93	636.42
Factor B	1	545489.34	545489.33	7184.35
Factor AB	1	87472.50	87472.49	1152.05

$F_{0.05}(3, 12) = 3.49$; $F_{0.05}(1, 12) = 4.75$; $F_{0.01}(3, 12) = 5.95$; $F_{0.01}(1, 12) = 9.33$



The results of ANOVA (Table 2) indicated that the individual and combined effects of HPβCD and Solutol HS15 in enhancing the solubility of ibuprofen were highly significant ($P < 0.01$). Solutol HS 15 alone gave highest enhancement (42.64 fold) in the solubility of ibuprofen. HPβCD alone gave 4.06 fold increases and in combination with Solutol HS 15 it gave 21.88 fold increases in the solubility of ibuprofen.

To evaluate the individual and combined effects of HPβCD and Solutol HS15 on the dissolution rate of ibuprofen, solid inclusion complexes of ibuprofen- HPβCD were prepared with and without Solutol HS15 as per 2²-factorial design. For this purpose two levels of HPβCD (0 and 1:2 ratio of drug : HPβCD) and two levels of Solutol HS15 (0 and 2%) were selected and the corresponding four treatments involved in the 2²-factorial study were ibuprofen pure drug (1); ibuprofen- HPβCD (1:2) inclusion complex (a); ibuprofen - Solutol HS15 (2%) binary complex (b) and ibuprofen- HPβCD (1:2) - Solutol HS15 (2%) inclusion complex (ab).

The CD complexes were prepared by kneading method. All the solid inclusion complexes of ibuprofen- HPβCD - Solutol HS15 prepared were found to be fine and free flowing powders. Low coefficient of variation (c.v.) values (< 1.0 %) in the percent drug content indicated uniformity of drug content in each batch of solid inclusion complexes

prepared. The dissolution rate of ibuprofen alone and from HPβCD complexes was studied in phosphate buffer of pH 7.2. The dissolution profiles are given in Fig 1.




Figure 1: Dissolution Profiles of Ibuprofen- HPβCD- Solutol HS15

Inclusion Complexes Prepared as per 2² Factorial Design

The dissolution of ibuprofen followed first order kinetics with r (correlation coefficient) above 0.9053. Dissolution efficiency (DE₃₀) values were calculated as suggested by Khan⁸. The dissolution parameters are given in Table 3. The dissolution of ibuprofen was rapid and higher in the case of ibuprofen- HPβCD - Solutol HS15 complex systems prepared when compared to ibuprofen pure drug as such.

Table 3: Dissolution Parameters of Ibuprofen – HPβCD- Solutol HS15 Inclusion Complexes

Formulation Code as per 2 ² Factorial Study	PD ₁₀ (%)		DE ₃₀ (%)		K ₁ x 10 ² (min ⁻¹)	
	X ± s.d	Increase in PD ₁₀ (no. of folds)	X ± s.d	Increase in DE ₃₀ (no. of folds)	X ± s.d	Increase in K ₁ (no. of folds)
1	26.21±3.05	--	26.21±1.51	-	1.01±0.03	-
A	84.14±2.04	3.21	80.79±1.45	3.08	10.91±1.46	10.80
B	87.57±4.14	3.34	85.67±0.87	3.27	19.81±1.70	19.1
ab	97.75±2.24	3.73	89.32±1.67	3.41	38.43±3.41	38.05

Table 4: ANOVA of Dissolution Rate (K₁) Data

Source of Variation	D F	S.S	MSS (SS/DF)	F – Ratio
Total	11	2330.19	211.83	
Treatment	3	2296.67	765.55	182.71
Error	8	33.51	4.19	
Factor A	1	619.06	619.06	147.75
Factor B	1	1623.45	1623.45	387.46
Factor AB	1	54.17	54.17	12.92

F_{0.05} (3, 8) = 4.07; F_{0.05} (1, 8) = 5.32; F_{0.01} (3, 8) = 7.59; F_{0.01} (1, 8) = 11.3

Table 5: ANOVA of Dissolution Efficiency (DE₃₀) Data

Source of Variation	D F	S.S	MSS (SS/DF)	F – Ratio
Total	11	7972.68	724.78	
Treatment	3	7956.73	2652.25	1330.21
Error	8	15.95	1.99	
Factor A	1	2543.89	2543.89	1275.87
Factor B	1	3467.30	3467.29	1738.99
Factor AB	1	1945.55	1945.55	975.77

F_{0.05} (3, 8) = 4.07; F_{0.05} (1, 8) = 5.32; F_{0.01} (3, 8) = 7.59; F_{0.01} (1, 8) = 11.3



The dissolution rate (K_1) and dissolution efficiency (DE_{30}) values were subjected to ANOVA to find out the significance of the main and combined effects of HP β CD and Solutol HS15 on the dissolution rate and dissolution efficiency of ibuprofen. The results of ANOVA (Tables 4 - 5) indicated that the individual main and combined (interaction) effects of HP β CD (Factor A) and Solutol HS15 (Factor B) in enhancing the dissolution rate (K_1) and dissolution efficiency (DE_{30}) were highly significant ($P < 0.01$).

HP β CD and Solutol HS15 alone gave respectively 10.80 and 19.10 fold increase in the dissolution rate of (K_1) of ibuprofen and in combination they gave a 38.05 fold increase in the dissolution rate (K_1) of ibuprofen. Thus, combination of HP β CD with Solutol HS15 resulted in a much higher enhancement in the dissolution rate of ibuprofen than is possible with them alone. Combination of HP β CD with Solutol HS15 also gave higher enhancement in the dissolution efficiency (DE_{30}) of ibuprofen.

CONCLUSION

1. The individual and combined effects of HP β CD and Solutol HS15 in enhancing the solubility of ibuprofen were highly significant ($P < 0.01$).
2. Solutol HS 15 alone gave highest enhancement (42.64 fold) in the solubility of ibuprofen. HP β CD alone gave 4.06 fold increases and in combination with Solutol HS 15 it gave 21.88 fold increases in the solubility of ibuprofen.
3. The individual main and combined (interaction) effects of HP β CD (Factor A) and Solutol HS15 (Factor B) in enhancing the dissolution rate (K_1) and dissolution efficiency (DE_{30}) were highly significant ($P < 0.01$).
4. HP β CD and Solutol HS15 alone gave respectively 10.80 and 19.10 fold increase in the dissolution rate of (K_1)

of ibuprofen and in combination they gave a 38.05 fold increase in the dissolution rate (K_1) of ibuprofen.

5. Combination of HP β CD with Solutol HS15 resulted in a much higher enhancement in the dissolution rate of ibuprofen than is possible with them alone.
6. Combination of HP β CD with Solutol HS15 also gave higher enhancement in the dissolution efficiency (DE_{30}) of ibuprofen.
7. Hence a combination of HP β CD and Solutol HS15 or Solutol HS15 alone is recommended to enhance the solubility, dissolution rate and dissolution efficiency of ibuprofen, a poorly soluble BCS class II drug.

REFERENCES

1. Chowdary, K.P.R. and Madhavi, B.L.R., Novel Drug Delivery Technologies for Insoluble Drugs, Indian Drugs, Indian Drugs, 42(9): 2005, 557-562.
2. Fromming, K.H. and Szejtli, J., Cyclodextrins in Pharmacy, Kluwer Academic Publications, Dordrecghi, p. 20, 1994.
3. Duchene, D. and Woussidjewe, D., in ed.: S. Dumitriu, Polysaccharides in Medical Applications, Marcel Dekker, New York, p. 575, 1996.
4. Thompson, D.O., Cyclodextrins-enabling Excipients: Their Present and Future Use in Pharmaceuticals. Crit. Rev. Ther. Drug Carrier Syst., 14 (1), 1997.
5. Hedges, A.R., Industrial Applications of Cyclodextrins. Chem. Rev., 98, 1998, 2035.
6. Rajebahadur, M., Zia, H., Nues, A. and Lee, C., Mechanistic Study of Solubility Enhancement of Nifedipine using Vitamin E TPGS or Solutol HS-15. Drug Delivery, 13(3), 2006, 201-6.
7. Sherry, Ku. and Ranga, Velagaleti., Solutol HS15 as a Novel Excipient. Pharmaceutical Technology, Nov. 2, 2010, 108-110.
8. Khan, K.A., The concept of dissolution efficiency. Journal of Pharmacy and Pharmacology, 27, 1975, 48-49.

